Agastiya Biotech
Agastiya Biotech is a next-generation oncology company leveraging systems biology, immunotherapy, and quantum biophysics to develop breakthrough cancer treatments. Its mission is to develop scientifically validated, non-toxic, and highly effective therapies that are affordable and accessible worldwide, with a focus on innovative drug development targeting cancer stem cells, genetic mutations, and immunomodulation.
Industries
Nr. of Employees
small (1-50)
Agastiya Biotech
Agastiya Biotech, 1902 Wright Place, Suite 200, Carlsbad, CA 92008-6583
Products
AB001 (investigational small-molecule therapeutic)
An orally bioavailable investigational small molecule described as tumor-agnostic with multi-modal mechanisms including pan-KRAS inhibition, PD-L1 modulation/degradation, miRNA/mRNA transcriptional repression, and cancer stem cell targeting; reported Phase I results and progression to Phase II.
ABREV001 (KRAS-targeted investigational small molecule)
A small-molecule candidate described as a pan-mutant KRAS inhibitor and degrader that binds mutant KRAS (GTP/GDP site interactions reported) and activates proteasomal degradation of mutant KRAS in preclinical models.
Topical botanical formulation for psoriasis (Ps-35)
A topical botanical drug candidate studied in clinical trials for chronic plaque psoriasis and licensed to a pharmaceutical company.
AB001 (investigational small-molecule therapeutic)
An orally bioavailable investigational small molecule described as tumor-agnostic with multi-modal mechanisms including pan-KRAS inhibition, PD-L1 modulation/degradation, miRNA/mRNA transcriptional repression, and cancer stem cell targeting; reported Phase I results and progression to Phase II.
ABREV001 (KRAS-targeted investigational small molecule)
A small-molecule candidate described as a pan-mutant KRAS inhibitor and degrader that binds mutant KRAS (GTP/GDP site interactions reported) and activates proteasomal degradation of mutant KRAS in preclinical models.
Topical botanical formulation for psoriasis (Ps-35)
A topical botanical drug candidate studied in clinical trials for chronic plaque psoriasis and licensed to a pharmaceutical company.
Services
Design and conduct of early-phase multi-center clinical trials including dose-escalation and expansion cohorts with biomarker and imaging endpoints.
In vitro cellular assays, xenograft efficacy models, immune profiling, and organ toxicology assessments to support IND/clinical filings.
In silico target prediction and AI-accelerated small-molecule discovery integrating advanced algorithmic and quantum biophysics concepts.
Design and conduct of early-phase multi-center clinical trials including dose-escalation and expansion cohorts with biomarker and imaging endpoints.
In vitro cellular assays, xenograft efficacy models, immune profiling, and organ toxicology assessments to support IND/clinical filings.
In silico target prediction and AI-accelerated small-molecule discovery integrating advanced algorithmic and quantum biophysics concepts.
Expertise Areas
- Small-molecule oncology drug discovery
- Pan-KRAS targeted therapy development
- Immuno-oncology mechanisms and checkpoint modulation
- Cancer stem cell-directed therapeutics
Key Technologies
- Small-molecule pan-KRAS inhibition
- PD-1/PD-L1 inhibition and targeted degradation
- miRNA-mediated gene silencing
- AI-driven molecular discovery integrating quantum biophysics concepts
News & Updates
Vopec Pharmaceuticals and Agastiya Biotech announced topline results from the Phase 1 study of AB001, demonstrating safety and tumor shrinkage in multiple metastatic cancers.
The US FDA granted Orphan Drug Designations for Pancreatic Cancer and AML for AB001, a small molecule PD-L1 checkpoint inhibitor.
Agastiya Biotech is pioneering quantum medicine, merging traditional wisdom with advanced science to develop safer, smarter, and holistic cures.
The company has discovered AB001 as a potential SARS-CoV-2 therapeutic, acting on ACE-2 and NSP15 to inhibit virus entry and replication.
Vopec Pharmaceuticals received approval to develop and test a new anti-cancer drug with potential for COVID-19 treatment.
Funds and know-how have been provided to develop drugs targeting Stage IV cancer and COVID-19.
Vopec Pharmaceuticals and Agastiya Biotech announced topline results from the Phase 1 study of AB001, demonstrating safety and tumor shrinkage in multiple metastatic cancers.
The US FDA granted Orphan Drug Designations for Pancreatic Cancer and AML for AB001, a small molecule PD-L1 checkpoint inhibitor.
Agastiya Biotech is pioneering quantum medicine, merging traditional wisdom with advanced science to develop safer, smarter, and holistic cures.
The company has discovered AB001 as a potential SARS-CoV-2 therapeutic, acting on ACE-2 and NSP15 to inhibit virus entry and replication.
Vopec Pharmaceuticals received approval to develop and test a new anti-cancer drug with potential for COVID-19 treatment.
Funds and know-how have been provided to develop drugs targeting Stage IV cancer and COVID-19.